FRESENIUS KABI

Amicus® Separator
Red Blood Cell Exchange (RBCX)





Multiple Options, Targeted Care.

Three protocols in one RBCX system

Three different procedure options allow physicians the flexibility to provide an individual treatment plan for patients.

Exchange

Removes the patient's RBCs and replaces them with compatible donor RBCs to achieve a target FCR, target End Hct and target fluid balance.

Depletion

Removes the patient's RBCs and replaces them with a prescribed replacement fluid to achieve a target End Hct.

Depletion/Exchange


Performs an RBC Depletion procedure, quickly followed by an RBC Exchange.

The Amicus Separator System is indicated to perform Red Blood Cell Exchange (RBCX), including Exchange and Depletion/Exchange procedures, for the transfusion management of Sickle Cell Disease in adults and children.

Precision Red Cell Removal[1]

Target FCR Accuracy and Reduction of HbS


Amicus RBCX accurately removes the patient's red blood cells (RBCs) while simultaneously infusing healthy donor cells. This data demonstrates the system's ability to successfully reach a target fraction of cells remaining (FCR), and reduction of hemoglobin S (HbS) post procedure.



Low extracorporeal kit volume and custom priming

Amicus employs a kit design with an extracorporeal volume (ECV) of 160 mL[2]. A low kit ECV helps to reduce the percent of patient total blood volume used to prime the kit.

For patients with lower total blood volume and/or lower hematocrit, Amicus offers a custom prime option (either partial or full). With the Partial Custom Prime option, the device has the ability to mix saline with the prime source fluid to achieve a desired hematocrit in the return line.



Auto-switching of replacement fluid

Utilizing the weight scales in conjunction with the replacement fluid pump, Amicus is able to recognize when a replacement fluid bag is empty and automatically switch fluids. This allows the operator to focus more on the patient.

Sterilization using irradiation

Sterilization of apheresis kits with irradiation avoids the risk of reactions related to patient exposure to residual ethylene oxide and eliminates the need for double priming the kit.

References

1. Fresenius Kabi RBCX Clinical Trial: AMIC-003-CMD – Evaluation of AMICUS Red Blood Cell Exchange and Depletion/Exchange Procedures in Sickle Cell Patients. Data on file at Fresenius Kabi USA
2. Fresenius Kabi Operator's Manual
3. Spectra Optia® Operator's Manual RBCX

Together with healthcare professionals, we are committed to making a positive difference with our technologies, training and support.

TH+ Technologies Training Support

Refer to the Instructions for Use and Operator's Manual for a complete list of warnings and precautions associated with the use of these products.

FRESENIUS KABI

US Headquarters:
Fresenius Kabi
Three Corporate Drive
Lake Zurich, IL 60047
Phone: (847) 550-2300
www.fresenius-kabi.us
AmicusTherapeutics@Fresenius-Kabi.com

All trademarks referred to are property of their respective owners.
Copyright © 2026 Fresenius Kabi AG. All rights reserved.

0004-AMTH-01-03/19